Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Drops By 18.1%

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 98,894 shares, a decrease of 18.1% from the January 29th total of 120,679 shares. Based on an average daily trading volume, of 74,849 shares, the days-to-cover ratio is presently 1.3 days. Currently, 1.5% of the company’s shares are short sold. Currently, 1.5% of the company’s shares are short sold. Based on an average daily trading volume, of 74,849 shares, the days-to-cover ratio is presently 1.3 days.

Lixte Biotechnology Trading Down 2.7%

NASDAQ LIXT traded down $0.08 during trading hours on Tuesday, hitting $2.85. 35,243 shares of the company’s stock were exchanged, compared to its average volume of 79,702. The firm has a market cap of $21.31 million, a price-to-earnings ratio of -2.42 and a beta of 0.93. The stock has a 50-day simple moving average of $3.40 and a 200 day simple moving average of $4.07. Lixte Biotechnology has a 1-year low of $0.64 and a 1-year high of $6.26.

Hedge Funds Weigh In On Lixte Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in LIXT. Axxcess Wealth Management LLC bought a new stake in shares of Lixte Biotechnology during the fourth quarter valued at approximately $54,000. XTX Topco Ltd acquired a new position in Lixte Biotechnology during the fourth quarter worth $57,000. Geode Capital Management LLC raised its holdings in Lixte Biotechnology by 25.9% during the fourth quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after buying an additional 10,722 shares during the last quarter. DRW Securities LLC lifted its stake in shares of Lixte Biotechnology by 11.6% in the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after buying an additional 5,645 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec grew its holdings in shares of Lixte Biotechnology by 83.6% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after buying an additional 42,530 shares during the last quarter. Institutional investors own 5.10% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Lixte Biotechnology in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Lixte Biotechnology currently has a consensus rating of “Sell”.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.